Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04830813 | Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | completed | Phase 3 | 184 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02819518 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | completed | Phase 3 | 882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2024 |
| clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT00924989 | A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma(GALACCTIC) | completed | Phase 3 | 139 | Astellas Pharma IncINDUSTRY | 9 | Nov 20, 2024 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03013504 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients(TROIKA) | completed | Phase 3 | 503 | Prestige Biopharma LimitedINDUSTRY | 13 | Nov 6, 2024 | clinicaltrials |
| NCT03430843 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 512 | BeiGeneINDUSTRY | 11 | Oct 26, 2024 | clinicaltrials |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01404156 | Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma(POWERRANGER) | completed | Phase 2 / Phase 3 | 29 | Dr. Gordon BuduhanOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01906216 | Sorafenib Chemoembolization Evaluation Controlled Trial(SELECT) | completed | Phase 3 | 199 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 | clinicaltrials |
| NCT03723941 | Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma(ACACIA) | completed | Phase 3 | 40 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | completed | Phase 3 | 214 | CinnagenINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT02856126 | HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | completed | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT04028050 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(MAURIS) | completed | Phase 3 | 155 | Hoffmann-La RocheINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04902885 | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | completed | Phase 3 | 95 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04047173 | RFA Versus SBRT for Recurrent Small HCC | completed | Phase 3 | 166 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02109146 | Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | completed | Phase 3 | 332 | Zhejiang UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00617981 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 701 | ImunonINDUSTRY | 11 | May 3, 2024 | clinicaltrials |
| NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 350 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT00304070 | Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor | completed | Phase 3 | 78 | Children's Oncology GroupNETWORK | 4 | Feb 28, 2024 | clinicaltrials |
| NCT04103398 | TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma(TREAT) | completed | Phase 3 | 162 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04878016 | A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC | completed | Phase 3 | 498 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT02650271 | Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01394263 | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | completed | Phase 3 | 59 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT01697384 | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | completed | Phase 3 | 138 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 540 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05197257 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | completed | Phase 3 | 39 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY | 12 | Sep 13, 2023 | clinicaltrials |
| NCT04914195 | Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | completed | Phase 3 | 155 | Bharat Serums and Vaccines LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2024source: clinicaltrials